目的观察吉西他滨联合厄洛替尼方案治疗进展期胰腺癌的疗效、临床获益反应和毒性反应。
ObjectiveTo evaluate the efficacy, clinical benefits and toxicities of gemcitabine combined with erlotinib for advanced pancreatic cancer.
主要观察终点为客观有效率、临床获益率、毒副反应发生率。
The primary end points were the overall rate of objective response, disease control rate and adverse effects rate.
主要观察终点为客观有效率、临床获益率、毒副反应发生率。
The primary end points were the overall rate of objective response, disease control rate and adverse effects rate.
应用推荐